Another SGLT2 inhibitor therapy has been recommended for listing on the PBS. At its March 2018 meeting the Pharmaceutical Benefits Advisory Committee recommended an Authority Required (Streamlined) listing for ertugliflozin for dual oral therapy with metformin or a sulfonylurea. The PBAC said it considered the evidence presented in the application from Merck Sharp & Dohme ...
Type 1 diabetes
New SGLT2 inhibitor and insulin get PBS listing recommendation
By Michael Woodhead
25 Apr 2018